Eligibilty

Gender



Age Group



More options for age range

Dates

Names

Showing 1 - 5 of 9 results
Page 1 of 2   

TAH-t Post Markey Surveillance Study

Principal Investigator: Jennifer Goerbig-Campbell, MD

Department:Department or Field of Study

The purpose of this study is to demonstrate that the results achieved in the original pivotal clinical investigation of 81 subjects from five clinical sites are generalizable to new clinical sites that complete the staff training defined in the SynCardia Systems, Inc. Training Manual and who enroll subjects who meet the intended use defined in the product Instructions for Use.

 

Please refer to www.clinicaltrials.gov identifier NCT00614510 for more information.

age group:18 to 99 years trial start date:August 1, 2006
Gender Preference:none Trial End Date: January 31, 2015
Contact Info:

Cardiomyopathy Treatment Program

Page Scovel, RN

phone:  319-356-1028

fax: 319-356-7087

email: page-scovel@uiowa.edu

Keywords: Artificial heart ; cardiac disease ; Cardiomyopathy ; CHF ; Congestive heart failure ; Heart ; heart disease ; Heart failure ; Mechanical circulatory support

Freedom Driver Study

Principal Investigator:Jennifer Goerbig-Campbell, MD

Department:Department or Field of Study

The purposes of this study are to confirm that the Freedom Driver System is a suitable pneumatic driver for clinically stable TAH-t subjects, and that patients and lay caregivers can be trained to manage the Freedom Driver System safely outside the hospital.

 

Please refer to www.clinicaltrials.gov identifier NCT00733447 for more information.

age group:18 to 99 years trial start date:March 1, 2010
Gender Preference:none Trial End Date: November 28, 2015
Contact Info:

Cardiomyopathy Treatment Program

Page Scovel, RN

phone:  319-356-1028

fax: 319-356-7087

email:  page-scovel@uiowa.edu

Keywords: Artificial heart ; cardiac disease ; Cardiomyopathy ; CHF ; Congestive heart failure ; Heart ; heart disease ; Heart Failure ; Mechanical Circulatory Support

Champion

Principal Investigator: Frances Johnson, MD

Department:Department or Field of Study

Champion: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients 

HF Pressure Measurement System

A pressure sensor is intended to be implanted into the pulmonary artery at the time of Swan-Ganz catheterization.

The primary hypothesis is that the TREATMENT group will have a significantly lower rate of HF-related hospitalizations than the CONTROL group. ( Time Frame: 6 months). This trial is closed to enrollment and is follow-up phase.

This trial is closed to enrollment and continues in follow up phase.

age group:18 to 99 years trial start date:September 1, 2007
Gender Preference:none Trial End Date: September 26, 2014
Contact Info:

Cardiomyopathy Treatment Program

Cynthia Larew RN  319-356-1028 pager # 2123

Keywords: cardiomyopathy ; device for treatment of heart failure ; Heart ; heart failure ; pulmonary artery pressure sensor

CUPID

Principal Investigator:Frances Johnson, MD

Department:Department or Field of Study

A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects With Heart Failure.  The purpose of this trial is to assess whether MYDICAR can reduce the frequency and/or delay heart failure related hospitalizations in persons with advanced heart failure when added to their maximal and optimized therapy.

Please refer to www.clinicaltrials.gov identifier NCT01643330

 for more information.

age group:0 to 80 years trial start date:November 1, 2012
Gender Preference:none Trial End Date: January 31, 2015
Contact Info:

A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure (CUPID-2b)

Cardiomyopathy Treatment Program

Cynthia Larew, RN BSN

phone:   319-356-1028

fax:  319-356-7087

email:  cynthia-larew@uiowa.edu

Keywords: cardiomyopathy ; CHF ; congestive heart failure ; Enter keyword ; gene therapy ; heart ; heart disease ; heart failure ; left ventricular failure ; undefined

LEPHT

Principal Investigator: KellyAnn Light-McGroary, MD

Department:Department or Field of Study

The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction

This study is closed to enrollment and is in follow-up phase.

Please refer to www.clinicaltrials.gov identifier NCT01065454 for more information. 

age group:18 to 80 years trial start date:April 1, 2010
Gender Preference:none Trial End Date: May 31, 2017
Contact Info:

Cardiomyopathy Treatment Program

Page Scovel, RN

phone:  319-356-1028

fax:  319-356-7087

email:  page-scovel@uiowa.edu

Keywords: cardiac disease ; Cardiomyopathy ; Congestive heart failure ; Heart ; Heart failure ; Left ventricular systolic dysfunction ; Pulmonary hypertension ; Pulmonary hypertension associated with left heart
Page 1 of 2
« 1 2 » 
Results per page
5 | 15 | 25

Clinical Research Studies

Filter By Started within
Show trials started in last 1 month
Your Selections

We'd welcome your feedback!

Please help us improve your experience on our website by completing a brief survey

Yes, I'll give feedback No, Thanks

x